Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $171.17 USD
Change Today +1.34 / 0.79%
Volume 3.6M
VRX On Other Exchanges
New York
As of 8:04 PM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

valeant pharmaceuticals inte (VRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/6/15 - $263.81
52 Week Low
10/15/14 - $111.41
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

valeant pharmaceuticals inte (VRX) Details

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer. It also provides Zovirax, an antiviral for recurrent herpes labialis and initial genital herpes; Syprine to treat patients with Wilson's disease; Elidel to treat atopic dermatitis; Prolensa for inflammation and pain following cataract surgery; Duromine, a weight loss drug; and Lotemax gel for post-operative inflammation and pain. In addition, the company offers PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe to rebuild and repair the skin barrier; ReNu Multiplus to lubricate and rewet soft contact lenses; Biotrue for healthy contact lens wear; Ocuvite, a lutein eye vitamin and mineral supplement; Boston, a cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; AntiGrippin for acute respiratory and respiratory viral diseases, and influenza; and Bedoyecta, a vitamin B complex product. Further, it provides SofLens daily disposable contact lenses; PureVision, a contact lens; various ophthalmic surgical products; Biotrue ONEday lens; medical device systems for aesthetic applications; and Bausch + Lomb Ultra, a contact lens. Additionally, the company offers Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Cardizem CD to treat hypertension and angina; and Latanoprost for the treatment of glaucoma. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.

16,800 Employees
Last Reported Date: 02/25/15
Founded in 1983

valeant pharmaceuticals inte (VRX) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.9M
President of Valeant Europe and General Manag...
Total Annual Compensation: $499.3K
Executive Vice President and Company Group Ch...
Total Annual Compensation: $5.8M
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $715.4K
Consultant and Director
Total Annual Compensation: $953.8K
Compensation as of Fiscal Year 2014.

valeant pharmaceuticals inte (VRX) Key Developments

Valeant Pharmaceuticals International, Inc. Announces FDA Acceptance of NDA Submission for Oral RELISTOR

Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review Valeant's New Drug Application for RELISTOR (methylnaltrexone bromide) Tablets for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of April 16, 2016. RELISTOR is a peripherally acting mu-opioid receptor antagonist specifically designed to block the constipating effects of opioid pain medications in the gastrointestinal tract. RELISTOR does not cross the blood-brain barrier, therefore relieving the distressing effects of the constipation without affecting the analgesic effect of the opioid. RELISTOR Subcutaneous Injection has been FDA approved since 2008 to treat OIC in patients with advanced illness who are receiving palliative care, and was approved in 2014 for the treatment of OIC in patients with chronic non-cancer pain.

Valeant Mulls Acquisitions

Valeant Pharmaceuticals International, Inc. (TSX:VRX) is seeking acquisitions. Mike Pearson, Chief Executive Officer of Valeant, said Valeant's strategy hasn't changed so much as the kinds of targets it can look at. Pearson said the company will continue to look at bigger deals. He said he looks at the recent market volatility as an opportunity.

Valeant Pharmaceuticals International, Inc. Announces Management Changes

Valeant Pharmaceuticals International, Inc. announced the addition of D. Robert Hale, Partner of ValueAct Capital, to its board of directors and the resignation of Jeffrey W. Ubben, CEO and CIO of ValueAct Capital, effective as of August 19, 2015. As a Partner and member of the investment team of ValueAct Capital, Hale has worked closely with the board and management team of Valeant since January 2011.  Hale will be the fourth Partner of ValueAct Capital to serve on the Valeant Board, following Mason Morfit, Brandon Boze, and Jeff Ubben. D. Robert Hale is a Partner of ValueAct Capital. Prior to joining ValueAct Capital in January 2011, Mr. Hale was a Principal with The Parthenon Group, working in both the Boston and Mumbai offices of Parthenon's strategic consulting practice, as well as in an investment role at Parthenon's long-short public equity vehicle, Strategic Value Capital. Mr. Hale is a director of MSCI, Inc.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRX:US $171.17 USD +1.34

VRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $41.16 USD +0.53
Astellas Pharma Inc ¥1,568 JPY +43.50
Celgene Corp $117.97 USD +0.99
Mylan NV $42.67 USD +0.44
Sun Pharmaceutical Industries Ltd 915.65 INR -10.55
View Industry Companies

Industry Analysis


Industry Average

Valuation VRX Industry Range
Price/Earnings 68.8x
Price/Sales 6.2x
Price/Book 8.8x
Price/Cash Flow 22.4x
TEV/Sales 2.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALEANT PHARMACEUTICALS INTE, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at